Kategoria: Aktualności

"The Present", film dokumentalny z udziałem Dimitri Poffé, jest już dostępny na Youtube

Dimitri Poffé is an already known member of the HD Community. After testing positive for Huntington’s Disease, Dimitri embraced a bicycle journey through South America. In this project, called Explore […]

PTC Therapeutics zawiera globalną umowę licencyjną i umowę o współpracy z Novartis w zakresie programu PTC518 dotyczącego choroby Huntingtona

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and […]

Sage Therapeutics zaprzestaje rozwoju dalzanemdoru w HD

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

Siła partnerstwa. Szwajcaria i Chiny dają przykład.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Livable Lives - nowa książka, która przedstawia historie ludzi dotkniętych HD na całym świecie.

PRESS RELEASE – October 25, 2024, Moscow, Idaho, USAWe are pleased to announce the launch of a new book about Huntington’s disease (HD) called, Livable Lives: Conversations with the Huntington’s […]

LoQus23 Therapeutics ogłasza finansowanie w wysokości 35 milionów funtów na rozwój nowego leku mającego na celu zahamowanie ekspansji somatycznej w chorobie Huntingtona.

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

FDA przyznaje oznaczenie Fast Track dla programu PTC518 dotyczącego choroby Huntingtona

PTC518 is an oral medication that reduces the production of the mutated Huntingtin protein that causes disease progression.   Programs with Fast Track designation can benefit from early interactions with the FDA, and may be […]

Pridopidyna firmy Prilenia stosowana w chorobie Huntingtona dopuszczona do europejskiego przeglądu pozwoleń na dopuszczenie do obrotu

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]

IROS, Prilenia i International Huntington's Disease Association współpracują nad pierwszym w historii badaniem choroby Huntingtona (HD) w regionie MENA.

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International […]

uniQure ogłasza pozytywną aktualizację danych okresowych wykazujących spowolnienie progresji choroby w badaniach fazy I/II AMT-130 dla HD

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” […]